BioAge Labs (NasdaqGS:BIOA) FY Conference Summary Company Overview - **Company**: BioAge Labs - **Focus**: Developing therapies for metabolic diseases by harnessing the biology of human aging through the BioAge Discovery Platform, which includes over 150 million molecular data points [2][3] Key Points and Arguments Clinical Development - **Lead Program**: BGE-102, an oral brain-penetrant NLRP3 inhibitor, is being developed to target cardiovascular risk and other aging-related diseases [3][4] - **Clinical Data**: Initial phase I trial data showed that 93% of obese patients with elevated CRP normalized their CRP levels to below 2, indicating best-in-class performance with an 86% reduction in hs-CRP from baseline [4][20] - **Upcoming Trials**: Full phase I data set will be released in the first half of the year, with a three-month monotherapy study planned for the second half [6][41] Mechanism of Action - **NLRP3 Inhibition**: The mechanism targets inflammation linked to various diseases, with a focus on cardiovascular and ophthalmological conditions [5][24] - **Safety Profile**: The drug has shown a favorable safety profile with mild to moderate adverse effects and no dose-limiting toxicity observed [10][14] Market Potential - **Cardiovascular Indications**: The drug aims to reduce cardiovascular risk factors, with CRP being a significant biomarker for MACE outcomes [24][25] - **Ophthalmology Focus**: Plans to explore indications in diabetic macular edema (DME) and geographic atrophy, leveraging the drug's ability to penetrate the brain and eye [27][28] Competitive Landscape - **Oral vs. Injectable**: The oral formulation of BGE-102 presents a significant advantage over current injectable therapies, potentially improving patient compliance and treatment outcomes [28][29] - **Unmet Needs**: There is a substantial unmet need in both DME and geographic atrophy, with current therapies showing modest efficacy [34][35] Additional Important Content - **Intellectual Property**: BioAge holds a strong IP position with granted patents covering the composition of matter and novel binding sites for NLRP3 [11][12] - **Collaborations**: Ongoing partnerships with Novartis and Lilly to discover drugs and drug targets, with interest in expanding collaborations [8][42] - **Future Catalysts**: Anticipated milestones include the release of phase I data, initiation of DME trials, and IND submissions for additional programs [41][42] Conclusion BioAge Labs is positioned to make significant advancements in the treatment of metabolic diseases through its innovative approach to NLRP3 inhibition, with promising clinical data and a strong pipeline of upcoming trials and collaborations. The focus on oral therapies could address critical unmet needs in the market, particularly in cardiovascular and ophthalmological indications.

Company Overview - BioAge Labs, Inc. is a clinical-stage biotechnology company focused on developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging [3] - The company's lead product candidate, BGE-102, is a small-molecule NLRP3 inhibitor aimed at treating cardiovascular risk and retinal diseases [3] - BioAge is also developing long-acting injectable and oral small molecule APJ agonists for obesity, alongside additional preclinical programs that leverage insights from human longevity data [3] Upcoming Events - BioAge will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026 [1] - CEO Kristen Fortney and CFO Dov Goldstein will participate in a fireside chat and one-on-one meetings during the conference [2] - A live webcast of the presentation will be available, with replays accessible on the company's investor website for 30 days post-event [2] Clinical Development - A Phase 1 SAD/MAD trial of BGE-102 is currently underway, with topline data, including additional MAD cohorts, expected in the first half of 2026 [3]

Core Viewpoint - BioAge Labs, Inc. has announced the pricing of its upsized underwritten public offering of 5,897,435 shares at $19.50 per share, aiming to raise approximately $115.0 million before expenses [1]. Group 1: Offering Details - The offering is expected to close on or about January 23, 2026, subject to customary closing conditions [1]. - BioAge has granted underwriters a 30-day option to purchase an additional 884,615 shares [1]. - Goldman Sachs & Co. LLC, Piper Sandler, and Citigroup are acting as joint book-running managers for the offering [2]. Group 2: Use of Proceeds - The net proceeds will be used to fund research, clinical and process development, and manufacturing of product candidates, including BGE-102, as well as working capital, capital expenditures, and reduction of indebtedness [3]. Group 3: Company Overview - BioAge is a clinical-stage biopharmaceutical company focused on developing therapeutic candidates for metabolic diseases by targeting human aging biology [6]. - The lead product candidate, BGE-102, is a small-molecule NLRP3 inhibitor for cardiovascular risk and retinal diseases, with a Phase 1 trial currently underway [6].

Group 1 - U.S. stock futures showed mixed results, with Dow futures declining approximately 0.1% [1] - Netflix reported fourth-quarter financial results that exceeded expectations but provided first-quarter guidance that fell short of estimates, leading to a significant drop in its stock price [2] - Netflix anticipates first-quarter revenue of $12.16 billion, slightly below the consensus estimate of $12.19 billion, and expects earnings per share of 76 cents, which is below the consensus estimate of 81 cents [2] Group 2 - Erasca Inc shares fell 6.2% to $9.20 following the announcement of a proposed public offering of $150 million [3] - Telix Pharmaceuticals experienced a 5.8% decline to $7.28, despite an analyst maintaining a Buy rating with a $20 price target [3] - Corvus Pharmaceuticals saw a 5.6% drop to $20.22 after commencing a $150 million offering of common shares and pre-funded warrants [3] - BIOAGE Labs Inc shares decreased by 5.6% to $20.13 after announcing a $75 million stock offering [3] - Kraft Heinz Co shares fell 5.3% to $22.51 after Berkshire Hathaway filed to sell up to 325 million shares of the company [3] - NovaBay Pharmaceuticals Inc shares dropped 5.2% to $6.16, following a 56% decline on Tuesday due to a $100 million ATM equity program announcement [3] - Okeanis Eco Tankers Corp shares decreased by 4.8% to $37.00 in pre-market trading [3]

Core Viewpoint - BioAge Labs, Inc. announced a proposed underwritten public offering to sell up to $75 million of its common stock, with an additional option for underwriters to purchase up to $11.25 million more, aimed at funding various corporate activities [1][3]. Group 1: Offering Details - The proposed offering is subject to market conditions and there is no assurance regarding its completion or terms [1]. - Goldman Sachs & Co. LLC, Piper Sandler, and Citigroup are acting as joint book-running managers for the offering [2]. - The shares are being offered under a registration statement that became effective on November 25, 2025 [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for research, clinical development, manufacturing of product candidates, working capital, capital expenditures, and reduction of indebtedness [3]. Group 3: Company Overview - BioAge is a clinical-stage biopharmaceutical company focused on developing therapeutic candidates for metabolic diseases by targeting human aging biology [6]. - The lead product candidate, BGE-102, is a small-molecule NLRP3 inhibitor for cardiovascular risk and retinal diseases, with a Phase 1 trial currently underway [6].

Core Insights - BioAge Labs, Inc. is expanding its BGE-102 development program into ophthalmology, specifically targeting diabetic macular edema (DME) as the initial proof-of-concept indication for its orally administered NLRP3 inhibitor [1][11] - BGE-102 has shown favorable tolerability in ongoing Phase 1 trials, with significant reductions in inflammatory biomarkers such as hsCRP, IL-6, and IL-1β, indicating its potential for broader anti-inflammatory benefits [1][3][10] - The company plans to initiate a Phase 1b/2a proof-of-concept trial in DME patients in mid-2026, with results expected in mid-2027, aiming to demonstrate target engagement and pharmacodynamics [6][7][13] Development Program - BGE-102 is a potent, orally available small molecule NLRP3 inhibitor, which has shown promise in preclinical models for preserving retinal vascular integrity and reducing age-related inflammatory markers [4][10] - The drug's mechanism targets the NLRP3 inflammasome, which is implicated in various retinal diseases, including DME and geographic atrophy, suggesting potential for expansion into additional indications [2][10] - The upcoming DME trial will run in parallel with a Phase 2a cardiovascular risk trial, with results for the latter anticipated in the second half of 2026 [1][13] Clinical Evidence - Clinical data supports the targeting of inflammation in retinal diseases, with injectable IL-6 inhibitors showing sustained visual acuity gains in patients with macular edema [5] - The primary endpoint for the DME trial will be the percent change in intraocular IL-6, with additional exploratory endpoints including best-corrected visual acuity and central subfield thickness [7] Anticipated Milestones - Key milestones include the completion of the Phase 1 trial with full data readout in the first half of 2026, initiation of the DME trial in mid-2026, and data readouts for both trials expected in mid-2027 [13]

BGE-102 (NLRP3 Inhibitor) - BGE-102 is a potential best-in-class NLRP3 inhibitor with an IC90 of 18 nM by human ex-vivo whole blood stimulation[23] - In obese participants, BGE-102 achieved an 86% reduction in hsCRP and normalized hsCRP (<2 mg/L) in 93% of patients after 14 days of dosing at 120 mg QD[8, 35] - Phase 1 clinical trial full data is anticipated in H1 2026[7, 32] - BGE-102 demonstrated ≥90% suppression of IL-1β for 24 hours after 14 days of dosing at 60 mg QD in healthy volunteers[35] - BGE-102 resulted in a 44-62% reduction in IL-6 in obese participants[66] APJ Agonist - Preclinical models suggest APJ agonism has the potential to double weight loss and fully restore body composition when combined with an incretin[8] - IND submission for APJ agonist is anticipated by 2026 YE[8] Financial Status - The company reported a strong balance sheet with $2959 million in cash, cash equivalents, and marketable securities as of September 30, 2025[164] Therapeutic Areas - Normalizing hsCRP (<2 mg/L) can drive a 25% reduction in MACE[83, 84]

Core Insights - BioAge Labs, Inc. announced positive interim data from the Phase 1 clinical trial of BGE-102, a novel NLRP3 inhibitor aimed at treating cardiovascular risk factors, showing significant reductions in inflammatory markers [1][4][9] Group 1: Clinical Trial Results - In a multiple ascending dose (MAD) cohort, BGE-102 at 120 mg once daily achieved an 86% median reduction in high-sensitivity C-reactive protein (hsCRP) at Day 14, with 93% of participants reaching hsCRP levels below 2 mg/L [2][7] - BGE-102 also demonstrated a 44% median reduction in serum IL-6 at Day 14, indicating its effectiveness in reducing systemic inflammation [6][12] - The drug achieved an 83% median reduction in hsCRP from a baseline of 4.85 mg/L at Day 7 and maintained an 86% reduction at Day 14 [7][9] Group 2: Safety and Tolerability - BGE-102 was well tolerated, with adverse events being infrequent, mild to moderate in severity, and self-limited, showing no dose-dependent pattern [12][14] - No dose-limiting toxicities were observed during the trial [12] Group 3: Future Development Plans - Full Phase 1 data, including additional MAD cohorts, is anticipated in the first half of 2026, with a Phase 2a study set to initiate in the same timeframe [1][13] - The Phase 2a study will evaluate BGE-102's effects on inflammatory biomarkers over a longer duration in patients with elevated cardiovascular risk [9][13] Group 4: Mechanism and Innovation - BGE-102 represents a structurally novel class of NLRP3 inhibitors with a unique mechanism and binding site, targeting age-related inflammation implicated in various diseases [14][15] - The drug's high brain penetration was confirmed, with cerebrospinal fluid concentrations exceeding the IC90 at doses of 60 mg and above [3][12]

Core Viewpoint - Premarket trading is showing significant activity with notable price movements indicating potential investment opportunities before the market opens [1] Premarket Gainers - Ventyx Biosciences, Inc. (VTYX) increased by 57% to $15.79 [3] - Cardio Diagnostics Holdings, Inc. (CDIO) rose by 36% to $4.02 [3] - Monte Rosa Therapeutics, Inc. (GLUE) saw a 28% increase to $20.54 [3] - Momentus Inc. (MNTS) gained 27% reaching $12.50 [3] - BioAge Labs, Inc. (BIOA) went up by 13% to $17.50 [3] - Neumora Therapeutics, Inc. (NMRA) increased by 11% to $2.03 [3] - Mobileye Global Inc. (MBLY) rose by 10% to $13.45 [3] - Society Pass Incorporated (SOPA) increased by 10% to $3.47 [3] - SU Group Holdings Limited (SUGP) saw an 8% rise to $6.32 [3] - Critical Metals Corp. (CRML) gained 7% reaching $12.73 [3] Premarket Losers - Evolution Metals & Technologies Corp. (EMAT) decreased by 28% to $15.20 [4] - Ascent Solar Technologies, Inc. (ASTI) fell by 12% to $4.65 [4] - Apogee Enterprises, Inc. (APOG) saw a 10% decline to $33.30 [4] - Next Technology Holding Inc. (NXTT) dropped by 8% to $8.49 [4] - AST SpaceMobile, Inc. (ASTS) decreased by 7% to $90.45 [4] - Nomadar Corp. (NOMA) fell by 7% to $3.66 [4] - EZGO Technologies Ltd. (EZGO) decreased by 7% to $1.99 [4] - Cohen & Company Inc. (COHN) saw a 6% decline to $28.30 [4] - PMGC Holdings Inc. (ELAB) dropped by 4% to $5.34 [4] - Anghami Inc. (ANGH) decreased by 3% to $4.49 [4]

Group 1: Market Overview - U.S. stocks experienced an upward trend, with the Dow Jones index increasing by approximately 200 points on Wednesday [1] Group 2: Dynavax Technologies Corp - Shares of Dynavax Technologies Corp rose significantly after Sanofi SA announced its acquisition for $15.50 per share in cash, totaling an equity value of around $2.2 billion [1] - The acquisition enhances Sanofi's position in the adult immunization market [1] - Dynavax shares surged by 38.6% to close at $15.44 on Wednesday [1] Group 3: Other Notable Stock Movements - Omeros Corp shares increased by 66.8% to $14.60 following FDA approval of YARTEMLEA for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy [3] - Edgewise Therapeutics Inc gained 23.8% to $26.94 after updates from the ongoing CIRRUS-HCM Phase 2 trial of EDG-7500 [3] - Agios Pharmaceuticals Inc shares surged by 17.9% to $29.00 after FDA approval of AQVESME for treating anemia in adults with thalassemia, priced at approximately $425,000 per patient per year [3] - Wheels Up Experience Inc saw a gain of 14.8% to $0.73 [3] - Travere Therapeutics Inc increased by 14.3% to $40.41 [3] - Coincheck Group NV shares rose by 12.5% to $2.88 [3] - Polestar Automotive Holding UK Plc jumped 11.8% to $16.92 after announcing a $300 million equity investment [3] - CapsoVision Inc gained 11.6% to $14.39 [3] - X4 Pharmaceuticals Inc increased by 9.5% to $4.52 [3] - Falcon's Beyond Global Inc shares rose by 9.4% to $18.35 following a $100 million mixed shelf offering [3] - BIOAGE Labs Inc jumped 8.8% to $14.37 [3] - Kodiak Sciences Inc gained 8.6% to $29.81 [3] - UiPath Inc increased by 7.9% to $17.23 after being announced as a replacement for Synovus Financial in the S&P MidCap 400 [3] - Immuneering Corp rose by 6.8% to $6.83, with an upcoming update on a clinical trial scheduled for January 7, 2026 [3] - Nike Inc shares gained 4.7% to $60.03 amid mixed investor sentiment regarding insider purchases and concerns over tariffs and demand in China [3] - Micron Technology Inc increased by 3.5% to $286.01 [3]